Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$274.82
pos +0.00
+0.00%
Today's Range: 272.87 - 278.10 | BIIB Avg Daily Volume: 1,739,200
Last Update: 03/24/17 - 4:00 PM EDT
Volume: 0
YTD Performance: 5.16%
Open: $0.00
Previous Close: $275.41
52 Week Range: $223.02 - $333.65
Oustanding Shares: 215,951,945
Market Cap: 59,475,325,172
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 11 11 11
Moderate Buy 0 1 1 1
Hold 6 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.75 1.53 1.53 1.53
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 16.27
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
16.27 16.30 30.30
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
3.71% 17.09% -4.60%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.80 0.70 0.18
Net Income 2.90 1.00 0.25
EPS 10.40 1.20 0.29
Earnings for BIIB:
EBITDA 4.28B
Revenue 10.13B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $5.00 $5.16 $20.94 $22.46
Number of Analysts 19 19 18 20
High Estimate $5.28 $5.38 $21.48 $23.82
Low Estimate $4.65 $4.98 $20.54 $19.18
Prior Year $4.79 $5.21 $20.22 $20.94
Growth Rate (Year over Year) 4.46% -0.88% 3.55% 7.27%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Jim Cramer

 | Mar 16, 2017 | 12:13 PM EDT
Many want to undo what's been done, but not enough to send the market down.
RMPIA

bearishBiogen downgraded at Leerink

Mar 16, 2017 | 7:13 AM EDT
BIIB was downgraded from Outperform to Market Perform, Leerink Partners said. $300 price target. Spinraza checks suggest a slow start.
RMPIA
By

Jim Cramer

 | Feb 27, 2017 | 12:27 PM EST
There are nearly too many surging sectors to count.
RMPIA
By

Jim Cramer

 | Feb 8, 2017 | 11:24 AM EST
Jim Cramer compares Allergan's growth to other pharma stocks.
RMPIA

bullishBiogen upgraded at Citi

Feb 7, 2017 | 7:01 AM EST
BIIB was upgraded to Buy, Citigroup said. $305 price target. See positive risk/reward for the MS product line.
RMPIA
By

James "Rev Shark" DePorre

 | Feb 1, 2017 | 10:51 AM EST
The Fed is simply not a market catalyst this time.
RMPIA
Jan 23, 2017 | 11:18 AM EST
A merger would be smart, profitable ... and attention-grabbing.
RMPIA
By

David Katz

 | Jan 8, 2017 | 2:00 PM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
RMPIA
By

David Katz

 | Jan 6, 2017 | 7:00 AM EST
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
RMPIA
By

Bret Jensen

 | Jan 3, 2017 | 11:00 AM EST
Drug giants with money to spend and a friendlier regulatory environment should spur deals.

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.